| Market Cap | 40.56M | P/E | - | EPS this Y | - | Ern Qtrly Grth | -76.20% |
| Income | 15.55M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 9.00% |
| Sales | 47.32M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 19.00% |
| Dividend | N/A | Price/Book | 1.38 | EPS next 5Y | 35.00% | 52W High Chg | -20.00% |
| Recommedations | - | Quick Ratio | 1.14 | Shares Outstanding | 1.02B | 52W Low Chg | 33.00% |
| Insider Own | 22.23% | ROA | 6.83% | Shares Float | 797.53M | Beta | -0.08 |
| Inst Own | - | ROE | 40.62% | Shares Shorted/Prior | 757.07K/1.34M | Price | 0.04 |
| Gross Margin | 45.82% | Profit Margin | 32.87% | Avg. Volume | 429,487 | Target Price | - |
| Oper. Margin | 22.73% | Earnings Date | Jun 29 | Volume | 868,790 | Change | -4.76% |
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.
